Shire PLC (SHP) Rating Reiterated by JPMorgan Chase & Co.
Shire PLC (LON:SHP)‘s stock had its “overweight” rating reiterated by JPMorgan Chase & Co. in a research note issued on Monday.
A number of other research firms have also recently issued reports on SHP. BNP Paribas restated an “outperform” rating and set a GBX 5,700 ($70.71) target price on shares of Shire PLC in a research note on Monday, August 1st. Royal Bank Of Canada restated an “outperform” rating on shares of Shire PLC in a research note on Wednesday, August 3rd. Deutsche Bank AG restated a “buy” rating and set a GBX 6,000 ($74.43) target price on shares of Shire PLC in a research note on Wednesday, August 3rd. Citigroup Inc. restated a “buy” rating on shares of Shire PLC in a research note on Wednesday, August 3rd. Finally, Goldman Sachs Group Inc. restated a “conviction-buy” rating and set a GBX 6,300 ($78.15) target price on shares of Shire PLC in a research note on Wednesday, August 3rd. One research analyst has rated the stock with a sell rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of GBX 5,992.27 ($74.34).
Shire PLC (LON:SHP) opened at 4801.50 on Monday. The firm’s market capitalization is GBX 43.22 billion. Shire PLC has a 52-week low of GBX 2,707.19 and a 52-week high of GBX 5,377.00. The firm has a 50-day moving average of GBX 4,857.25 and a 200-day moving average of GBX 4,744.39.
In related news, insider Dominic Blakemore purchased 133 shares of the firm’s stock in a transaction that occurred on Friday, September 30th. The shares were bought at an average cost of GBX 5,010 ($62.15) per share, with a total value of £6,663.30 ($8,266.10).
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.